Visit link:
Basilea announces licensing of a novel first-in-class antifungal program from Fox Chase Chemical Diversity Center

Continued here:
Tiziana Life Sciences to participate in a Fireside Chat At the B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

Excerpt from:
Saniona Changes Date of Annual Report for 2021

Continue reading here:
Vistin Pharma ASA: First quarter 2022 financial results

Read more from the original source:
Palisade Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference and Biotech Showcase

View post:
AviadoBio’s Gene Therapy Candidate Receives Orphan Designation from Food and Drug Administration and European Commission in Frontotemporal Dementia

See the original post:
Total number of shares and voting rights in Zealand Pharma at December 30, 2021

Follow this link:
Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2...

More here:
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022

Read the rest here:
Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs

Read more from the original source:
Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults With Type 2 Diabetes

Read the original post:
Basilea receives USD 10 million milestone payment related to approval of antifungal Cresemba® (isavuconazole) in China

See the rest here:
Statera Biopharma Announces First Patient Dosed in Study of STAT-205 for Acute COVID

More here:
TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy

See original here:
Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities

See more here:
Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021

Read the original:
Oncternal Therapeutics Announced Pre-Clinical Data from ONCT-534, an Androgen Receptor N-Terminal-Domain-Binding Small Molecule Degrader, Was Accepted...

See the rest here:
Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference

Read the original here:
Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19...

Continued here:
Eurobio Scientific offers a new proprietary test for simultaneous detection of the SARS-CoV-2 virus and characterization of its new mutations of...